CaloCurb CLINICAL Starter Pack

Calocurb® CLINICAL is a practitioner-exclusive supplement that supports appetite control by working with the body’s natural hormonal signals. It features Amarasate®, a clinically studied extract of New Zealand bitter hops, delivered in a delayed-release capsule designed to reach the small intestine where it activates bitter taste receptors. This triggers the release of key satiety hormones including GLP-1, CCK and PYY, which work together to significantly reduce hunger, cravings, and caloric intake. Fast-acting and plant-based, Calocurb® CLINICAL offers a targeted, science-driven approach to supporting healthy weight management. Clinical Applications Reduces Appetite and Food Cravings Supports Long-Term Weight Management Stimulates Natural GLP-1, CCK and PYY Release Complements Lifestyle and Pharmaceutical Weight Loss Strategies Enhances Adherence to Intermittent Fasting and Time-Restricted Eating In 2019, the first clinical study on Amarasate® was conducted in a randomized, double-blind trial investigating its appetite suppressive effects during a 24-hour, water-only fast. Participants given Amarasate® or placebo at hours 16 and 20 were evaluated for hunger and satiety with a standard visual analog scale (VAS) every 30 minutes after capsule administration. Amarasate® participants reported an 80% reduction in hunger elevation scores compared to the placebo group. In a comparable water-fast study conducted in women, Amarasate® supplementation led to a 100% suppression of hunger elevation and a 120% reduction in food cravings relative to placebo. A more expansive study of adult men sought to correlate the subjective reduction in hunger from the first study with anorexigenic biomarkers, specifically GLP-1, CCK and PYY. The study also sought to investigate which was more efficacious, intragastric or intraduodenal delivery of Amarasate®. In the randomized, double-blind study, the subjects were given either placebo, intraduodenal Amarasate® (delayed-release capsule), or intragastric Amarasate® (immediate-release capsule) one hour before an ad libitum meal and subsequent snack. Both Amarasate® delivery methods had significant elevations in GLP-1, CCK and PYY; however, the intragastric capsule also had significantly more adverse events than the intraduodenal capsule likely due to the high amount of TAS2R bitter receptors in the stomach. Intraduodenal delivery of Amarasate® resulted in 600% elevation from baseline of GLP-1 and CCK, and 50% elevation of PYY. In a 24-week real-world, double-blind, placebo-controlled trial of 128 overweight or obese adults, Amarasate® or placebo was taken twice daily before a meal. At the study conclusion, the Amarasate® group had lost 5.4% body weight after a calculated adjustment for the 2.0 lb of muscle mass gain. Bioelectrical Impedence Analysis demonstrated a 9.9 lb fat mass loss including 32.5 cm2 of visceral fat. Additionally, Amarasate® significantly suppressed the normal elevations of hunger and food cravings during weight loss. CLINICAL CONSIDERATIONS Amarasate® is a potent and effective appetite modulator, offering a targeted approach to supporting satiety and caloric control. It can be used independently or integrated into a comprehensive strategy for weight loss or maintenance. Calocurb® CLINICAL may be co-administered with weight-loss medications to help manage breakthrough hunger or used during medication tapering to support appetite control. Alternatively, Calocurb® CLINICAL can also be used as needed to support adherence to time-restricted eating or to help manage appetite and craving increases that may occur premenstrually.